Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL
Status:
RECRUITING
Trial end date:
2030-09-30
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the efficacy of combining pirtobrutinib, lisaftoclax, and rituximab (PVR) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have received at least one prior line of systemic therapy and to explore a more effective treatment strategy for this patient population.
Phase:
PHASE2
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University